NAS
NBIX icon

Nykredit A/S’s Neurocrine Biosciences NBIX Stock Holding History

Nykredit A/S’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$5.19M Buy
+30,811
New +$4.57M 0.02% 476

Other funds holding NBIX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Nykredit A/S's NBIX Position: Q2 2026 in Review

Nykredit A/S opened a new position in Neurocrine Biosciences (NBIX) in Q2 2026: 30,811 shares worth $5.19M. The stake represents 0.02% of the portfolio and ranks #476 among its holdings.

781 funds tracked by Wall St. Rank hold NBIX as of Q2 2026.

  • Nykredit A/S held 30,811 shares of Neurocrine Biosciences worth $5.19M as of Q2 2026.
  • Neurocrine Biosciences was a new Nykredit A/S position in Q2 2026.
  • Neurocrine Biosciences made up 0.02% of Nykredit A/S's portfolio in Q2 2026, its #476 holding.
  • 781 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2026.

Based on Nykredit A/S's 13F filing for Q2 2026, filed 13 Aug 2026.